Do analysts prefer COGT or TRLV?

Cogent Biosciences presently has a consensus price target of $43.73, indicating a potential upside of 12.14%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cogent Biosciences is more favorable than Trulieve Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86 Trulieve Cannabis 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable earnings & valuation, COGT or TRLV?

Trulieve Cannabis has higher revenue and earnings than Cogent Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Trulieve Cannabis $1.17B 1.44 N/A N/A N/A

Is COGT or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Trulieve Cannabis N/A N/A N/A

Do analysts prefer TRLV or LNTH?

Lantheus has a consensus target price of $101.86, indicating a potential downside of 3.94%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Trulieve Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trulieve Cannabis 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lantheus 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73

Which has higher earnings & valuation, TRLV or LNTH?

Lantheus has higher revenue and earnings than Trulieve Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.17B 1.44 N/A N/A N/A Lantheus $1.55B 4.46 $233.56M $4.15 25.55

Do analysts prefer TRLV or SRRK?

Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 1.09%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Trulieve Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trulieve Cannabis 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Scholar Rock 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 4 Strong Buy rating(s) 3.12

Which has preferable valuation and earnings, TRLV or SRRK?

Trulieve Cannabis has higher revenue and earnings than Scholar Rock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.17B 1.44 N/A N/A N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is TRLV or SRRK more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Trulieve Cannabis N/A N/A N/A Scholar Rock N/A -163.52% -96.67%

Does the media favor TRLV or SRRK?

In the previous week, Scholar Rock had 10 more articles in the media than Trulieve Cannabis. MarketBeat recorded 11 mentions for Scholar Rock and 1 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 0.20 beat Scholar Rock's score of -0.14 indicating that Trulieve Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 1 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, CNTA or TRLV?

Trulieve Cannabis has higher revenue and earnings than Centessa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Centessa Pharmaceuticals N/A N/A -$197.53M -$1.79 N/A Trulieve Cannabis $1.17B 1.44 N/A N/A N/A

Is CNTA or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Centessa Pharmaceuticals N/A -60.37% -44.17% Trulieve Cannabis N/A N/A N/A

Do analysts recommend TWST or TRLV?

Twist Bioscience currently has a consensus target price of $84.30, suggesting a potential downside of 5.33%. Given Twist Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Twist Bioscience is more favorable than Trulieve Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Trulieve Cannabis 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, TWST or TRLV?

Trulieve Cannabis has higher revenue and earnings than Twist Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $376.57M 14.73 -$77.67M -$1.33 N/A Trulieve Cannabis $1.17B 1.44 N/A N/A N/A

Does the media refer more to TWST or TRLV?

In the previous week, Twist Bioscience had 6 more articles in the media than Trulieve Cannabis. MarketBeat recorded 7 mentions for Twist Bioscience and 1 mentions for Trulieve Cannabis. Twist Bioscience's average media sentiment score of 0.65 beat Trulieve Cannabis' score of 0.20 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Trulieve Cannabis (TRLV) Competitors

$8.78 -0.15 (-1.68%)

As of 01:27 PM Eastern

Compare

TRLV vs. COGT, LNTH, SRRK, CNTA, and TWST

Should you buy Trulieve Cannabis stock or one of its competitors? MarketBeat compares Trulieve Cannabis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trulieve Cannabis include Cogent Biosciences (COGT), Lantheus (LNTH), Scholar Rock (SRRK), Centessa Pharmaceuticals (CNTA), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

How does Trulieve Cannabis compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Trulieve Cannabis (NYSE:TRLV) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Cogent Biosciences presently has a consensus price target of $43.73, indicating a potential upside of 12.14%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cogent Biosciences is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Trulieve Cannabis' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Trulieve Cannabis	N/A	N/A	N/A

In the previous week, Trulieve Cannabis had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 1 mentions for Trulieve Cannabis and 0 mentions for Cogent Biosciences. Trulieve Cannabis' average media sentiment score of 0.20 beat Cogent Biosciences' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the news media.

Company	Overall Sentiment
Cogent Biosciences	Neutral
Trulieve Cannabis	Neutral

Trulieve Cannabis has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Trulieve Cannabis	$1.17B	1.44	N/A	N/A	N/A

Summary

Trulieve Cannabis beats Cogent Biosciences on 5 of the 9 factors compared between the two stocks.

How does Trulieve Cannabis compare to Lantheus?

Trulieve Cannabis (NYSE:TRLV) and Lantheus (NASDAQ:LNTH) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Lantheus has higher revenue and earnings than Trulieve Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.17B	1.44	N/A	N/A	N/A
Lantheus	$1.55B	4.46	$233.56M	$4.15	25.55

In the previous week, Trulieve Cannabis had 1 more articles in the media than Lantheus. MarketBeat recorded 1 mentions for Trulieve Cannabis and 0 mentions for Lantheus. Trulieve Cannabis' average media sentiment score of 0.20 beat Lantheus' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
Trulieve Cannabis	Neutral
Lantheus	Neutral

Lantheus has a net margin of 18.05% compared to Trulieve Cannabis' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Lantheus	18.05%	29.32%	15.00%

99.1% of Lantheus shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lantheus has a consensus target price of $101.86, indicating a potential downside of 3.94%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Lantheus beats Trulieve Cannabis on 9 of the 12 factors compared between the two stocks.

How does Trulieve Cannabis compare to Scholar Rock?

Trulieve Cannabis (NYSE:TRLV) and Scholar Rock (NASDAQ:SRRK) are both pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

91.1% of Scholar Rock shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Scholar Rock had 10 more articles in the media than Trulieve Cannabis. MarketBeat recorded 11 mentions for Scholar Rock and 1 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 0.20 beat Scholar Rock's score of -0.14 indicating that Trulieve Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	1 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trulieve Cannabis has higher revenue and earnings than Scholar Rock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.17B	1.44	N/A	N/A	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 1.09%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Trulieve Cannabis' return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Scholar Rock	N/A	-163.52%	-96.67%

Summary

Scholar Rock beats Trulieve Cannabis on 7 of the 11 factors compared between the two stocks.

How does Trulieve Cannabis compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Trulieve Cannabis (NYSE:TRLV) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Trulieve Cannabis has higher revenue and earnings than Centessa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Trulieve Cannabis	$1.17B	1.44	N/A	N/A	N/A

Trulieve Cannabis' return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Trulieve Cannabis	N/A	N/A	N/A

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Centessa Pharmaceuticals currently has a consensus target price of $41.33, indicating a potential upside of 2.06%. Given Centessa Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Centessa Pharmaceuticals is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Trulieve Cannabis had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 1 mentions for Trulieve Cannabis and 0 mentions for Centessa Pharmaceuticals. Trulieve Cannabis' average media sentiment score of 0.20 beat Centessa Pharmaceuticals' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the news media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
Trulieve Cannabis	Neutral

Summary

Centessa Pharmaceuticals and Trulieve Cannabis tied by winning 5 of the 10 factors compared between the two stocks.

How does Trulieve Cannabis compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Trulieve Cannabis (NYSE:TRLV) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Twist Bioscience currently has a consensus target price of $84.30, suggesting a potential downside of 5.33%. Given Twist Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Twist Bioscience is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Trulieve Cannabis has higher revenue and earnings than Twist Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	14.73	-$77.67M	-$1.33	N/A
Trulieve Cannabis	$1.17B	1.44	N/A	N/A	N/A

In the previous week, Twist Bioscience had 6 more articles in the media than Trulieve Cannabis. MarketBeat recorded 7 mentions for Twist Bioscience and 1 mentions for Trulieve Cannabis. Twist Bioscience's average media sentiment score of 0.65 beat Trulieve Cannabis' score of 0.20 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trulieve Cannabis has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Trulieve Cannabis' return on equity of 0.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Trulieve Cannabis	N/A	N/A	N/A

Summary

Twist Bioscience beats Trulieve Cannabis on 6 of the 10 factors compared between the two stocks.

Get Trulieve Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRLV vs. The Competition

Export

Metric	Trulieve Cannabis	Medicinal Chemicals Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$1.68B	$1.56B	$4.39B	$23.27B
Dividend Yield	N/A	N/A	16.13%	4.01%
P/E Ratio	N/A	N/A	23.82	30.50
Price / Sales	1.44	2.20	152.35	20.62
Price / Cash	N/A	0.27	34.70	25.43
Price / Book	N/A	373.88	14.70	4.70
Net Income	N/A	-$1.41M	$116.30M	$1.07B
7 Day Performance	-8.19%	-8.19%	-2.25%	-1.12%
1 Month Performance	N/A	-65.04%	-1.28%	1.20%
1 Year Performance	N/A	-61.28%	8.95%	15.30%

Trulieve Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRLV Trulieve Cannabis	1.3203 of 5 stars	$8.78 -1.7%	N/A	N/A	$1.67B	$1.17B	N/A	9,000	News Coverage
COGT Cogent Biosciences	1.1426 of 5 stars	$40.01 +1.4%	$43.73 +9.3%	+327.9%	$6.74B	N/A	N/A	80
LNTH Lantheus	2.2689 of 5 stars	$103.41 +0.6%	$101.86 -1.5%	+30.6%	$6.69B	$1.54B	24.92	1,193
SRRK Scholar Rock	1.4149 of 5 stars	$56.56 +2.2%	$56.00 -1.0%	+59.4%	$6.63B	N/A	N/A	140	News Coverage Insider Trade
CNTA Centessa Pharmaceuticals	1.1459 of 5 stars	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TRLV) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trulieve Cannabis (TRLV) Competitors

TRLV vs. COGT, LNTH, SRRK, CNTA, and TWST

How does Trulieve Cannabis compare to Cogent Biosciences?

Summary

How does Trulieve Cannabis compare to Lantheus?

Summary

How does Trulieve Cannabis compare to Scholar Rock?

Summary

How does Trulieve Cannabis compare to Centessa Pharmaceuticals?

Summary

How does Trulieve Cannabis compare to Twist Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trulieve Cannabis (TRLV) Competitors

TRLV vs. COGT, LNTH, SRRK, CNTA, and TWST

How does Trulieve Cannabis compare to Cogent Biosciences?

Do analysts prefer COGT or TRLV?

Is COGT or TRLV more profitable?

Does the media prefer COGT or TRLV?

Which has preferable earnings & valuation, COGT or TRLV?

Summary

How does Trulieve Cannabis compare to Lantheus?

Which has higher earnings & valuation, TRLV or LNTH?

Does the media favor TRLV or LNTH?

Is TRLV or LNTH more profitable?

Do institutionals and insiders believe in TRLV or LNTH?

Do analysts prefer TRLV or LNTH?

Summary

How does Trulieve Cannabis compare to Scholar Rock?

Do insiders & institutionals have more ownership in TRLV or SRRK?

Does the media favor TRLV or SRRK?

Which has preferable valuation and earnings, TRLV or SRRK?

Do analysts prefer TRLV or SRRK?

Is TRLV or SRRK more profitable?

Summary

How does Trulieve Cannabis compare to Centessa Pharmaceuticals?

Which has higher earnings and valuation, CNTA or TRLV?

Is CNTA or TRLV more profitable?

Do insiders & institutionals believe in CNTA or TRLV?

Do analysts recommend CNTA or TRLV?

Does the media refer more to CNTA or TRLV?

Summary

How does Trulieve Cannabis compare to Twist Bioscience?

Do analysts recommend TWST or TRLV?

Which has higher valuation & earnings, TWST or TRLV?

Does the media refer more to TWST or TRLV?

Is TWST or TRLV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLV vs. The Competition

Trulieve Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools